Translating Evidence Into Practice: Maintenance Immunotherapy and Evolving Sequencing in Advanced Urothelial Carcinoma

Maintenance immunotherapy reshapes advanced bladder cancer care, extending survival after platinum chemotherapy while easing relapse anxiety with better-tolerated checkpoint blockade options.

After platinum chemo shrinks metastatic bladder cancer, experts weigh maintenance therapy vs watchful waiting for older patients with comorbidities.

In this segment, the speaker reviews real-world clinical decision-making for advanced urothelial (bladder) carcinoma after first-line platinum-based chemotherapy.

This segment explores how long-term survival data and real-world experience inform decisions about maintenance immunotherapy in advanced urothelial (bladder) cancer.

This segment focuses on long-term maintenance therapy for advanced urothelial (bladder) carcinoma, emphasizing both clinical outcomes and real-world patient experience.

This segment examines how real-world evidence is used to guide maintenance therapy and treatment sequencing in advanced urothelial (bladder) cancer.

This segment presents an 84-year-old patient with metastatic urothelial (bladder) cancer, multiple comorbidities, and limited functional status who has completed carboplatin plus gemcitabine with stable disease but notable treatment-related cytopenias.

This segment explores how clinicians balance quality of life and survival when using maintenance therapy in advanced urothelial (bladder) carcinoma, while also looking ahead to future treatment directions.

This segment focuses on how clinicians use real-world evidence to individualize treatment sequencing in advanced urothelial (bladder) cancer, especially when patients do not fit classic clinical trial profiles.